Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

NCT06499233

Status	RECRUITING
Phase	Phase 4
Sponsor	Tongji Hospital
Enrollment	800 participants

Key Eligibility Criteria

Inclusion (3)

- The patient was diagnosed with AIIRD according to the International Classification of Diseases and had received steroids or immunosuppressive therapy;
- The patient had not received standard PJP treatment before enrollment, including the first-line treatment drug TMP/SMZ, or other second-line treatment drugs (including Pentamidine, Atorvastatin, Caspofungin, etc.);
- The patient was at least 18 years old at the time of enrollment;

Exclusion (7)

- Serious health problems or diseases, including (but not limited to) the following: severe liver damage (ALT, AST elevated above normal value by more than 5 times), severe renal insufficiency (GFR \< 30mL/min or Scr \> 445umol/L), severe myelosuppression (Hb \< 65g/L, PLT \< 25×10\^9/L or neutrophils \< 0.5×10\^9/L);
- Screening test indicates infection with human immunodeficiency virus (HIV), history of lymphomatous hyperplasia of the lymphatic tissue or any malignant tumor of any organ system within the past 5 years, or history of organ transplantation;
- Participants with a history of allergy to sulfonamide drugs, megaloblastic anemia due to folate deficiency;
- Pregnant and lactating women;
- Any medical or psychological condition that the investigator believes would interfere with the participant's ability to comply with the protocol or complete the study;

... and 2 more (see full listing online)

Locations (1 total)

Tongji Hospital, Wuhan, Hubei, China